Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

VTLG MCID: VTL009 MIFTS: 39	Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (VTLG) Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases, Smell/Taste diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 ⁵⁸ ¹³

Generalized Vitiligo ⁷⁶ ⁷⁴

Vitiligo ⁷⁶ ⁷⁴

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 ⁷⁴

Vamas6 ⁵⁸

Vtlg ⁷⁶

Characteristics:

OMIM:

⁵⁸

Inheritance:
? epistatically interacting multiple autosomal recessive

HPO:

³³

vitiligo-associated multiple autoimmune disease susceptibility 6:
Inheritance autosomal recessive inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases Immune diseases Smell/Taste diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM ⁵⁸ 193200

MeSH ⁴⁵ D014820

MedGen ⁴³ C0042900 C3277701

SNOMED-CT via HPO ⁷⁰ 21119008 258211005 400096001 more

UMLS ⁷⁴ C0042900 C1304470 C1847835

Sources

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

UniProtKB/Swiss-Prot : ⁷⁶ Vitiligo: A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6, also known as generalized vitiligo, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and deafness, congenital, with vitiligo and achalasia, and has symptoms including pruritus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22). The drugs Bimatoprost and Ophthalmic Solutions have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and thyroid, and related phenotypes are vitiligo and nevus

Description from OMIM: 193200

Sources

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases in the Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 family:

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 386)

#	Related Disease	Score
1	vitiligo-associated multiple autoimmune disease susceptibility 1	13.0
2	deafness, congenital, with vitiligo and achalasia	12.4
3	alopecia universalis onychodystrophy vitiligo	12.3
4	vitiligo, progressive, with mental retardation and urethral duplication	12.1
5	autoimmune disease 1	12.0
6	spastic paraplegia 23, autosomal recessive	11.9
7	alopecia areata	11.7
8	schrander-stumpel theunissen hulsmans syndrome	11.5
9	autoimmune polyglandular syndrome type 3	11.5
10	halo nevi	11.3
11	piebald trait	11.3
12	vogt-koyanagi-harada disease	11.3
13	hemifacial atrophy, progressive	11.3
14	autoimmune atrophic gastritis	11.3
15	alezzandrini syndrome	11.2
16	autoimmune disease 2	11.2
17	autoimmune disease 3	11.2
18	autoimmune disease 4	11.2
19	stiff-person syndrome	11.1
20	hereditary spastic paraplegia 23	11.0
21	ermine phenotype	11.0
22	hypoadrenocorticism, familial	11.0
23	autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia	11.0
24	nijmegen breakage syndrome	11.0
25	lelis syndrome	11.0
26	t-cell receptor-alpha/beta deficiency	11.0
27	hypopigmentation of eyelid	11.0
28	combined immunodeficiency with skin granulomas	11.0
29	gemignani syndrome	11.0
30	melanoma	10.6
31	alopecia	10.5
32	psoriasis	10.5
33	autoimmune disease	10.4
34	thyroiditis	10.4
35	dermatitis	10.4
36	alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity	10.3
37	neutrophil migration	10.3
38	hepatitis	10.3
39	lichen planus	10.3
40	lupus erythematosus	10.2
41	lymphomatous thyroiditis	10.2
42	hepatitis c	10.2
43	mycosis fungoides	10.2
44	hypothyroidism	10.2
45	dermatitis, atopic	10.1
46	skin carcinoma	10.1
47	localized scleroderma	10.1
48	hashimoto thyroiditis	10.1
49	squamous cell carcinoma	10.1
50	rheumatoid arthritis	10.1

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Sources

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

³³

#	Description	HPO Frequency	HPO Source Accession
1	vitiligo ³³		HP:0001045
2	nevus ³³		HP:0003764

Symptoms via clinical synopsis from OMIM:

⁵⁸

Skin:
vitiligo
halo nevi

Misc:
onset after birth
no predilection for ventral skin

Clinical features from OMIM:

193200

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

pruritus, exanthema

Sources

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bimatoprost

Approved, Investigational

Phase 4

155206-00-1

5311027

Synonyms:

(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide

(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide

(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide

155206-00-1

15M

267244-98-4

5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)

AC1NSJUW

AGN 192024

AGN-192024

Bimataprost [USAN:INN:BAN]

Bimatoprost

Bimatoprost (JAN/USAN/INN)

Bimatoprost [USAN:INN:BAN]

bimatoprostum

Bimatoprostum

CHEBI:39562

CHEBI:51230

CHEMBL1200963

CID5311027

D02724

DB00905

DB06863

I06-1275

I06-1277

Latisse

LS-181817

Lumigan

Lumigan (TN)

NCGC00181745-01

UNII-QXS94885MZ

ZINC04474405

Ophthalmic Solutions

Phase 4

Pharmaceutical Solutions

Phase 4

Dermatologic Agents

Phase 4,Phase 1

Antihypertensive Agents

Phase 4

Simvastatin

Approved

Phase 2

79902-63-9

54454

Synonyms:

(+)-Simvastatin

(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate

[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate

2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester

2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

79902-63-9

AC-1530

AC1L1H1F

AKOS005111006

ARONIS24119

BCBcMAP01_000007

BIDD:GT0769

Bio-0672

BPBio1_001001

BRD-K22134346-001-05-8

BRN 4768037

BSPBio_000909

BSPBio_002337

Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester

Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester

Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester

butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta

C25H38O5

CCRIS 7558

CHEBI:9150

CHEMBL1064

Cholestat

CID54454

Coledis

Colemin

Corolin

CPD000718785

D00434

D019821

Denan

DivK1c_006991

DRG-0320

Eucor

HMS1570N11

HMS1922H13

HMS2089D12

HMS2093E06

HSDB 7208

InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

KBio1_001935

KBio2_002197

KBio2_004765

KBio2_007333

KBio3_001557

KBioGR_001244

KBioSS_002197

Kolestevan

KS-1113

L 644128-000U

Labistatin

Lipex

Lipinorm

Liponorm

Lipovas

Lodales

LS-46264

Medipo

MK 0733

MK 733

MK-0733

MK733

MK-733

MLS001304029

MLS001333077

MLS001333078

MLS002154038

Modutrol

MolPort-002-507-345

MolPort-002-885-862

NCGC00017324-01

NCGC00017324-02

NCGC00017324-03

nchembio790-comp16

Nivelipol

Nor-vastina

Pantok

Pepstatin

Prestwick_171

Prestwick0_000865

Prestwick1_000865

Prestwick2_000865

Prestwick3_000865

Rechol

Rendapid

S1792_Selleck

S6196_SIGMA

SAM002589969

Simcor

Simovil

Simvast CR

simvastatin

Simvastatin

Simvastatin & Primycin

Simvastatin (JAN/USP/INN)

Simvastatin [Usan:Ban:Inn]

Simvastatin [USAN:INN:BAN]

Simvastatin lactone

Simvastatin, Compactin

Simvastatina

Simvastatina [Spanish]

Simvastatine

Simvastatine [French]

Simvastatinum

Simvastatinum [Latin]

Simvotin

Sinvacor

Sinvascor

Sivastin

SMR000718785

SPBio_001881

SPBio_002830

SpecPlus_000895

Spectrum_001717

SPECTRUM1504236

Spectrum2_001671

Spectrum3_000669

Spectrum4_000632

Spectrum5_001428

Statin

STK801938

Synvinolin

TNP00259

UNII-AGG2FN16EV

Valemia

Vasotenal

Velostatin

Vytorin

ZINC03780893

Zocor

Zocor (TN)

Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin

Zocord

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 2

Lipid Regulating Agents

Phase 2

Anticholesteremic Agents

Phase 2

Antimetabolites

Phase 2

Hypolipidemic Agents

Phase 2

Tacrolimus

Approved, Investigational

Phase 1

104987-11-3

6473866 445643 439492

Synonyms:

(-)-FK 506

(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone

104987-11-3

109581-93-3 (Hydrate)

15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,

3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone

8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN

AC-1182

AC1L1K7H

AC1L97GB

AC1L9IBU

Advagraf

AKOS005145901

Ambap104987-11-3

Ambap5429

Anhydrous tacrolimus

Anhydrous, tacrolimus

BCBcMAP01_000194

Bio-0921

Bio2_000470

Bio2_000950

BRD-K35452788-001-02-1

BSPBio_001279

BSPBio-001279

C01375

C44H69NO10

CCRIS 7124

CHEBI:100924

CHEBI:61049

CHEMBL1200738

CID11158639

CID11556866

CID439492

CID445643

CID5372

CID5472317

CID6426916

CID6436007

CID6473866

CID6536850

CID6610362

CID6912836

CID9832283

CID9853905

CID9918805

CID9940643

CID9963169

Cilag brand OF tacrolimus

CPD000466356

CPD-10016

D08556

DB00864

DivK1c_001040

FK 506

FK5

Fk-506

FK506

FK-506

FR 900506

FR900506

FR-900506

FT-0082660

Fujimycin

Fujisawa brand OF tacrolimus

Graceptor

HMS1362O21

HMS1792O21

HMS1990O21

HMS2051C18

HMS2093M19

HMS503O21

IDI1_001040

IDI1_002225

Janssen brand OF tacrolimus

K506

KBio1_001040

KBio2_000619

KBio2_003187

KBio2_005755

KBio3_001097

KBio3_001098

KBioGR_000619

KBioSS_000619

L 679934

L-679934

LCP-Tacro

LMPK04000003

LS-64247

MLS000759471

MLS001424054

Modigraf

MolPort-003-666-518

NCGC00163470-01

NCGC00163470-02

NCGC00163470-03

NCGC00163470-04

NCGC00179232-01

NChemBio.2007.16-comp1

nchembio.2007.23-comp2

NINDS_001040

NSC717865

Prograf

Prograf (TN)

Prograft

Protopic

Protopy

S5003_Selleck

SAM001246677

SMR000466356

Tacarolimus

tacrolimus

Tacrolimus

Tacrolimus (anhydrous)

Tacrolimus (INN)

Tacrolimus (Prograf?)

Tacrolimus anhydrous

tacrolimus hydrate

Tacrolimus, anhydrous

Tsukubaenolide

UNII-Y5L2157C4J

Calcitriol

Approved, Nutraceutical

Phase 1

32222-06-3

5280453 134070

Synonyms:

(1a,3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol

(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol

(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol

(1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol

(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol

(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol

(1S,3R,5Z,7E)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol

(1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol

(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol

(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol

(5Z,7E)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol

(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol

(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol

1 alpha, 25 Dihydroxy 20 epi vitamin D3

1 alpha, 25-Dihydroxy-20-epi-vitamin D3

1 alpha,25 Dihydroxycholecalciferol

1 alpha,25 Dihydroxyvitamin D3

1 alpha,25-Dihydroxycholecalciferol

1 alpha,25-Dihydroxyvitamin D3

1,25 (OH)2 D3

1,25 Dihydroxy 20 epi vitamin D3

1,25 Dihydroxycholecalciferol

1,25 Dihydroxyvitamin D3

1,25(OH)2-20epi-D3

1,25(OH)2-20EPi-D3

1,25-(OH)2D3

1,25-(OH)2-D3

1,25(OH)2D3 & CD4

1,25(OH2)D3

1,25D3

1,25-DHCC

1,25-dihydroxy vitamin D3

1,25-dihydroxy-20-epi-Vitamin D3

1,25-Dihydroxy-20-epi-vitamin D3

1,25-dihydroxycholecalciferol

1,25-Dihydroxycholecalciferol

1,25-DIHYDROXYCHOLECALCIFEROL

1,25-Dihydroxycholecaliferol

1,25-Dihydroxyvitamin D

1,25-Dihydroxyvitamin D3

1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3

17936_FLUKA

17936_SIGMA

1a,25(OH)2D3

1a,25-(OH)2D3

1a,25-Dihydroxycholecalciferol

1a,25-Dihydroxyvitamin D3

1-a-25-Dihydroxyvitamin D3

1-alpha,-1,25-Dihydroxyvitamin D3

1alpha,25(OH)2D3

1alpha,25(OH)2-D3

1alpha,25-Dihydroxycholecalciferol

1-alpha,25-Dihydroxycholecalciferol

1alpha,25-Dihydroxyvitamin D

1alpha,25-Dihydroxyvitamin D3

1-alpha,25-Dihydroxyvitamin D3

1-alpha-25-dihydroxyvitamin D3

1-alpha-25-Dihydroxyvitamin D3

1db1

1α,25(OH)2D3

1α,25-dihydroxycholecalciferol

1α,25-dihydroxyvitamin D3

1-α-25-dihydroxyvitamin D3

20 Epi 1alpha,25 dihydroxycholecaliferol

20-epi-1alpha,25-dihydroxycholecaliferol

20-Epi-1alpha,25-dihydroxycholecaliferol

25-Dihydroxycholecalciferol

32222-06-3

5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol

9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol

9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol

9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4

Abbott brand OF calcitriol

AC-1859

AC1NQX1S

alpha,25-Dihydroxyvitamin D3, 1

Alphapharm brand OF calcitriol

Ambap32222-06-3

Asentar

BCBcMAP01_000160

BML2-E03

Bocatriol

BSPBio_001287

C01673

Calcijex

Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol

calcitriol

Calcitriol

Calcitriol (JAN/USAN/INN)

Calcitriol [USAN:INN:BAN:JAN]

Calcitriol abbott brand

Calcitriol alphapharm brand

Calcitriol cryopharma brand

Calcitriol galderma brand

Calcitriol gry brand

Calcitriol jenapharm brand

Calcitriol kyramed

Calcitriol kyramed brand

Calcitriol leo brand

Calcitriol medice brand

Calcitriol nefro

Calcitriol renacare brand

Calcitriol roche brand

Calcitriol-nefro

CalcitriolNefro

Calcitriolum

Calcitriolum [INN-Latin]

CCRIS 5522

CD-2027

CHEBI:17823

CHEMBL846

CID5280453

CPD000466393

Cryopharma brand OF calcitriol

D00129

D1530_SIGMA

D3, 1 alpha,25-Dihydroxyvitamin

D3, 1,25-Dihydroxy-20-epi-vitamin

D3, 1,25-Dihydroxyvitamin

Decostriol

Dihydroxyvitamin D3

DN 101

DN-101

EINECS 250-963-8

Galderma brand OF calcitriol

Gry brand OF calcitriol

HMS1361A09

HMS1791A09

HMS1989A09

HMS2051F06

HMS2089N03

Hoffmann la roche brand OF calcitriol

Hoffmann-la roche brand OF calcitriol

HSDB 3482

IDI1_033757

Jenapharm brand OF calcitriol

KyraMed brand OF calcitriol

KyraMed, calcitriol

leo Brand OF calcitriol

LMST03020258

LS-53093

MC1288

MC-1288

Medice brand OF calcitriol

MLS000759536

MLS001424122

MolPort-002-045-698

NCGC00161327-01

NCGC00161327-04

Osteotriol

RenaCare brand OF calcitriol

Renatriol

ro 21-5535

Ro 215535

Ro 21-5535

Ro-21-5535

Rocaltrol

Rocaltrol (TN)

Roche brand OF calcitriol

S1466_Selleck

SAM001246772

Silkis

Sitriol

SMR000466393

Soltriol

Spectrum5_002061

Tirocal

Topitriol

Toptriol

U 49562

Vectical

vit D

ZINC03924790

Calcium

Approved, Nutraceutical

Phase 1

7440-70-2

271

Synonyms:

Blood coagulation factor XIII

Ca(2+)

Ca2+

Calcio

Calcium

Calcium element

CALCIUM ion

Calcium, doubly charged positive ion

Calcium, elemental

Coagulation factor XIII

Elemental calcium

Factor XIII

Factor XIII a chain

Factor XIII a-chain

Factor XIII transamidase

Factor XIII, coagulation

Fibrin stabilizing factor

Fibrinase

Kalzium

Laki lorand factor

Laki-lorand factor

Stabilizing factor, fibrin

Transamidase, factor XIII

XIII, coagulation factor

Vasoconstrictor Agents

Phase 1

Calcium, Dietary

Phase 1

Immunologic Factors

Phase 1

Trace Elements

Phase 1

Bone Density Conservation Agents

Phase 1

Immunosuppressive Agents

Phase 1

Calcipotriene

Phase 1

Calcineurin Inhibitors

Phase 1

Hormones

Phase 1

Vitamins

Phase 1

Micronutrients

Phase 1

Nutrients

Phase 1

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo	Not yet recruiting	NCT03487042	Phase 4	Bimatoprost 0.03% ophthalmic solution
2	Clinical Trial of Simvastatin to Treat Generalized Vitiligo	Completed	NCT01517893	Phase 2	Simvastatin;Placebo
3	The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo	Not yet recruiting	NCT03234673	Phase 1	Tacrolimus ointment;calcipotriol ointment;NB-UVB
4	HI-Light Pilot Trial for Vitiligo: Hand Held NB-UVB for Early or Focal Vitiligo at Home	Completed	NCT01478945	Not Applicable
5	Long-term Follow-up in Patients Affected With Acrofacial Vitiligo	Not yet recruiting	NCT01459055

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :

methoxsalen

monobenzone

trioxsalen

Sources

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Sources

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

⁴²

Skin, T Cells, Thyroid, Myeloid, Bone Marrow, Ovary, Pituitary

Sources

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

(show top 50) (show all 94)

#	Title	Authors	Year
1	The effect of NB-UVB on noncultured melanocyte and keratinocyte transplantation in treatment of generalized vitiligo using two different donor-to-recipient ratios. ( 30280485 )	Tawfik YM...Tohamy AMA	2019
2	The role of IFIH1 gene rs1990760 and rs2111485 single-nucleotide polymorphisms in generalized vitiligo predisposition ( 30761886 )	Onan D...Yal??n B	2019
3	Narrow-band UVB effects on cutaneous vitamin D receptor expression and serum 25-hydroxyvitamin D in generalized vitiligo. ( 29080365 )	El-Hanbuli HM...Mahmoud RH	2018
4	Plasma & urinary catecholamines & urinary vanillylmandelic acid levels in patients with generalized vitiligo. ( 29998874 )	Basnet B...Gupta S	2018
5	Paradoxically dark spontaneous repigmentation: a rare complication of generalized vitiligo. ( 27785821 )	Agrawal S...Lim HW	2017
6	Oxidation products are increased in patients affected by non-segmental generalized vitiligo. ( 28551758 )	Vaccaro M...Gangemi S	2017
7	Differential Expression of Nitric Oxide Synthase Isoforms nNOS and iNOS in Patients with Non-Segmental Generalized Vitiligo. ( 29186858 )	Vaccaro M...Squadrito F	2017
8	IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo. ( 27388717 )	Vaccaro M...Gangemi S	2016
9	Combination therapy of orally administered glycyrrhizin and UVB improved active-stage generalized vitiligo. ( 27464024 )	Mou KH...Li P	2016
10	The changes of gene expression profiling between segmental vitiligo, generalized vitiligo and healthy individual. ( 27470284 )	Wang P...Xu A	2016
11	Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation. ( 25376752 )	Tembhre MK...Gupta S	2015
12	Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo. ( 25427848 )	Vaccaro M...Gangemi S	2015
13	Participation of T cell immunoglobulin and mucin domain-3 (TIM-3) and its ligand (galectin-9) in the pathogenesis of active generalized vitiligo. ( 25784621 )	Tembhre MK...Sharma VK	2015
14	Generalized vitiligo in a dog with primary hypoadrenocorticism. ( 26104920 )	Malerba E...Fracassi F	2015
15	Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. ( 23590677 )	van Geel N...Speeckaert R	2014
16	Distribution patterns in generalized vitiligo. ( 23651011 )	Speeckaert R...van Geel N	2014
17	Lack of Association between PTPN22 Gene +1858 C>T Polymorphism and Susceptibility to Generalized Vitiligo in a Turkish Population. ( 24648691 )	Akbas H...Atay AE	2014
18	Generalized vitiligo post radiotherapy in a breast cancer patient. ( 25022394 )	Vajrala G...Fernandes DJ	2014
19	Can systemically generated reactive oxygen species help to monitor disease activity in generalized vitiligo? A pilot study. ( 25484381 )	Pradhan R...Chatterjee S	2014
20	Association of generalized vitiligo with MHC class II loci in patients from the Indian subcontinent. ( 23303446 )	Birlea SA...Spritz RA	2013
21	Risk of generalized vitiligo is associated with the common 55R-94A-247H variant haplotype of GZMB (encoding granzyme B). ( 23321921 )	Ferrara TM...Spritz RA	2013
22	The association between a single nucleotide polymorphism rs11966200 in MHC region and clinical features of generalized vitiligo in Chinese Han population. ( 23516070 )	Tang J...Yang S	2013
23	Decreased regulatory T-cells and CD4(+) /CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo. ( 23574980 )	Dwivedi M...Begum R	2013
24	Evaluation of total oxidant and antioxidant status in localized and generalized vitiligo. ( 23601201 )	Akoglu G...Kilinc F	2013
25	T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. ( 23680073 )	Tembhre MK...Gupta S	2013
26	Association of NLRP1 genetic variants and mRNA overexpression with generalized vitiligo and disease activity in a Gujarat population. ( 23773036 )	Dwivedi M...Begum R	2013
27	Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo. ( 23777204 )	Dwivedi M...Begum R	2013
28	Methotrexate for the treatment of generalized vitiligo. ( 24227963 )	Alghamdi K...Khurrum H	2013
29	Segmental and generalized vitiligo: both forms demonstrate inflammatory histopathological features and clinical mosaicism. ( 24249893 )	Attili VR...Attili SK	2013
30	A single nucleotide polymorphism rs9468925 of MHC region is associated with clinical features of generalized vitiligo in Chinese Han population. ( 21951294 )	Liu J...Zhang X	2012
31	Study of clinical, biochemical and immunological factors determining stability of disease in patients with generalized vitiligo undergoing melanocyte transplantation. ( 22329760 )	Rao A...Singh G	2012
32	Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation. ( 22402439 )	Jin Y...Spritz RA	2012
33	Treatment of generalized vitiligo with anti-TNF-α Agents. ( 22453596 )	Alghamdi KM...Ezzedine K	2012
34	Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. ( 22548391 )	Hallaji Z...Damavandi MR	2012
35	Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. ( 22561518 )	Jin Y...Spritz RA	2012
36	Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. ( 22649532 )	Lili Y...Ming L	2012
37	The association of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D levels with generalized vitiligo. ( 22762534 )	Li K...Gao TW	2012
38	Wart with depigmented halo and generalized vitiligo. ( 24031144 )	Ito T...Yamamoto O	2012
39	Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. ( 21085187 )	Birlea SA...Spritz RA	2011
40	Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. ( 21326295 )	Jin Y...Spritz RA	2011
41	Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. ( 21616559 )	Ezzedine K...Taieb A	2011
42	Asymptomatic papules and plaque in a patient with generalized vitiligo. ( 21772607 )	Reddy IS...Swain M	2011
43	Recent progress in the genetics of generalized vitiligo. ( 21777851 )	Spritz RA	2011
44	Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. ( 21778811 )	Narita T...Suzuki T	2011
45	Prothrombin G20210A mutation, hypogonadotropic hypogonadism, and generalized vitiligo-related ischemic stroke in a young adult. ( 20504218 )	Varoglu AO...Tatar A	2010
46	Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8. ( 19890347 )	Birlea SA...Spritz RA	2010
47	Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. ( 20410501 )	Jin Y...Spritz RA	2010
48	Narrowband ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of generalized vitiligo. ( 20456387 )	Gamil H...Ghonemy S	2010
49	Common variants in FOXP1 are associated with generalized vitiligo. ( 20526340 )	Jin Y...Spritz RA	2010
50	Genetic association of NALP1 with generalized vitiligo in Jordanian Arabs. ( 20574744 )	Alkhateeb A...Qarqaz F	2010

Sources

Genes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Genes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (2 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	PTPN22	Protein Tyrosine Phosphatase Non-Receptor Type 22	Protein Coding	300	Causative variation ⁷⁶
2	VAMAS6	Vitiligo	Genetic Locus	50	Genetic linkage ⁵⁸ Susceptibility factor ⁵⁸

Sources

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

⁷⁶

#	Symbol	AA change	Variation ID	SNP ID
1	PTPN22	p.Arg620Trp	VAR_022605	rs2476601

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	KIF1B	NM_015074.3(KIF1B): c.4387C> T (p.Arg1463Cys)	single nucleotide variant	Uncertain significance	rs757850683	GRCh37	Chromosome 1, 10425479: 10425479
2	KIF1B	NM_015074.3(KIF1B): c.4387C> T (p.Arg1463Cys)	single nucleotide variant	Uncertain significance	rs757850683	GRCh38	Chromosome 1, 10365421: 10365421

Sources

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6.

Sources

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Sources

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Sources

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (VTLG)

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Characteristics:

OMIM:

HPO:

Classifications:

External Ids:

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases in the Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 family:

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Symptoms via clinical synopsis from OMIM:

Clinical features from OMIM:

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 74 / NDF-RT 52 :

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Genes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Genes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (2 elite genes):

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :